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Preliminary investigation of a new serum marker 
for ovarian cancer
Abstract
Objectives: The long-term survival rate of patients with carcinoma of the ovary is poor, because this condition is 
usually diagnosed at an advanced stage of the disease. A reliable diagnostic and screening test is still lacking. 
Therefore, a serological test for a novel ovarian tumour antigen was developed and investigated in a clinical 
setting. This report describes this investigation, the aim of which was to provide data to decide whether the test 
warrants a further, large-scale trial.
Methods: Serum collected from 25 patients with ovarian carcinoma, 24 healthy controls and 25 control patients 
with non-carcinomatous ovarian disorders was tested. The test utilises a monoclonal antibody, designated 
SMO47, to capture the tumour antigen and a normal form of the antigen from serum. Only the tumour antigen 
is detected by biotinylated Maakia amurensis lectin, which binds specifically to the sialic acid on the tumour 
antigen. 
Results: The sensitivity for the carcinoma patient group was 60% and the specificity for the control patient 
group was 76% when a cut-off value for 100% specificity in the healthy controls was used. The area under the 
receiver-operator characteristic curve was 0. 8200. CA125 tests were done on all serum, and the results compared 
graphically. The tumour antigen in the serum was very stable and did not seem to be affected by freezing or long 
storage at 4°C.
Conclusions: The results of this first application of the new test are encouraging and warrant further investigation 
and testing of larger numbers of subjects to obtain more significant values for the sensitivity and specificity.
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Introduction
Ovarian cancer is often referred to as the “silent 
killer”, because of late presentation and difficulty 
in diagnosis. Epithelial ovarian cancer is a common 
disease in countries with a larger elderly population. 
The incidence in American women aged 75-79 years is 
high at 57.3 /100 000 women/year.1
Ovarian carcinoma can often be successfully treated if it 
is diagnosed at an early stage, but the diagnosis is often 
a death sentence because of late presentation and 
detection. The mortality associated with the diagnosis 
of epithelial ovarian cancer is invariably high, and 
statistics from the USA confirm that ovarian carcinoma 
is the most deadly gynaecological cancer after the age 
of 45 years.1 The inaccessible anatomical position of the 
ovaries makes it difficult to detect clinical signs. Clinical 
examination is therefore not very helpful in making the 
diagnosis, because many subtle signs may be missed.2
Background: screening with biomarkers
Ovarian cancer has a relatively low prevalence, and 
the risk of morbidity due to false positive tests may 
outweigh the benefits. For a good screening test with 
a minimum positive predictive value of about 10%, a 
specificity of greater than 99.6% and sensitivity greater 
than 75% would be necessary.
The most widely used biochemical marker for carcinoma 
of the ovary is the tumour antigen CA125 initially 
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described by Dr Robert Bast.3 At present, it is widely used 
as a marker of response to therapy.4 CA125 is secreted 
by coelomic and Müllerian epithelium, and a cut-off 
value of 30-35 units/ml is generally accepted as normal 
for postmenopausal patients.5 However, CA125 is a fairly 
non-specific screening test when used alone, and levels 
may be raised in various noncancerous conditions.6 
CA125 may be raised in 50% of cases with stage I ovarian 
carcinoma, and in more than 90% of cases with advanced 
disease.  There is generally a lead time of approximately 
1.5-1.9 years from the time that the CA125 becomes 
elevated to the time of detection of clinical disease.  
Multimodal screening strategies show the most 
promise. A UK group showed that sequential CA125 
and transvaginal ultrasound may achieve specificity 
to detect ovarian carcinoma of 99.9%, with a positive 
predictive value of 26.8% (four operations/one case of 
ovarian carcinoma).7,8 Results from the long-awaited 
and very well-designed UKCTOCS (United Kingdom 
Collaborative Trial of Ovarian Cancer Screening) study 
have recently been published.9 A large group of women 
were randomised to one of three groups in a ratio of 2:1:1. 
Half of the participants (n= 101 359) were randomised 
to no intervention, while the rest were divided between 
two screening strategies. One group (n=50  640) had 
annual CA125 measurements (interpreted with a risk of 
cancer algorithm), followed by transvaginal ultrasound 
if abnormal. This was referred to as the multimodal 
screening (MMS) group. Another group (n=50  639) 
underwent only annual transvaginal ultrasound.  There 
was a significantly better specificity for detection of 
invasive epithelial ovarian and tubal carcinomas in the 
MMS group when compared to the ultrasound-only 
group. The morbidity cost, measured as the number 
of operations needed to diagnose one invasive cancer, 
was 35 operations per case in the ultrasound group and 
only three operations per case in the MMS group. The 
authors concluded that the sensitivity for both screening 
strategies were encouraging. However, before final 
conclusions can be reached about whether screening 
will change mortality, further study is needed. In 
reaction to these results, a group form Leuven in Belgium 
responded by calling the results “encouraging”.10 
The Prostate, Lung, Colorectal and Ovarian (PLCO) 
cancer screening trial that is ongoing in the USA aims 
to include 155 000 men and women, and the screening 
tool that will be utilised for ovarian cancer is CA125 
combined with transvaginal scanning.11 The results of 
this trial should be available in the next 5 to 10 years.
CA125 has also been used in combination other 
biochemical markers, for example OVX1 and 
marcrophage colony-stimulating factor (M-CSF), to 
improve sensitivity.12 OVX1 and M-CSF, in combination 
with CA125, increased the sensitivity from 66% to 
76% to detect early-stage disease, but also decreased 
the specificity from 96% to 83%. Of the large number 
of biomarkers that have been tested in the serum of 
patients with ovarian cancer, two promising tests were 
reported to be human epididymis protein 4 (HE4),13 
and a soluble form of mesothelin.14 However, alone or 
in combination with CA125, they have also not been 
accepted as general screening tests. Other biomarkers 
mentioned in the literature include CA72-4,15 M-CSF,16 
prostasin,17 osteopontin,18 inhibin,19 and human 
anterior gradient 2 (AGR2).20 Despite all these potential 
candidates, there is still no single sensitive and specific 
biomarker for ovarian cancer.
Background: SMO47
The monoclonal antibody with clone designation 
SMO47, which is used in the assay described in this 
report, reacts well with formalin-fixed and routinely 
processed tissues, and its reactivity with tumour 
tissues21 and cytological preparations of peritoneal 
fluids22 has been described previously. It also reacts with 
normal epithelium of the respiratory tract, fallopian 
tubes, salivary glands, endometrium, uterine cervix, 
small bowel and ovary, and partly with mesothelium 
(RH Laeng, unpublished observations). The antigen 
to which SMO47 binds is a high-molecular-weight 
glycoprotein that occurs in a normal form in human 
male and female serum, and in a tumour-specific form 
in serum from female patients with carcinoma of the 
ovary and in spent culture medium of the ovarian 
carcinoma cell line UWOV1,23 which expresses high 
levels of the antigen associated with the cellular 
glycocalyx. As was shown previously,21 the normal form 
is of heterogeneous molecular weight and contains 
either low level or no sialic acid residues, whereas 
the tumour-specific form is homogeneous, of higher 
molecular weight, and sialylated and sulphated. 
Based on the previous findings of the high sialic acid 
content of the tumour antigen, the serological assay 
was designed to detect only the tumour antigen. 
The epitope to which the antibody binds seems to 
be repeated, as the antigen could be detected by an 
enzyme-linked immunosorbent assay (ELISA) in which 
the SMO47 antibody was used both as capture and 
detecting antibody (not shown). However, such an 
assay would detect both the normal and the tumour 
antigen. Therefore, Maackia amurensis lectin I (MAL1), 
which binds specifically to sialic acid in glycoproteins, 
was used to detect the sialic acid in the tumour antigen. 
Thus, although both antigens are captured by the plate-
bound antibody, only the tumour antigen is detected.
Study design
Patients
Three separate groups of patients were included 
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in this study. Group A consisted of 25 patients with 
carcinoma of the ovary confirmed by histology. All 
patients in group A were newly diagnosed with 
carcinoma and patients with recurrent disease were 
not included. Group B consisted of 24 healthy female 
control subjects who were admitted for voluntary tubal 
ligation and underwent laparoscopy so that other 
subclinical peritoneal diseases could be excluded. 
(Patients requesting sterilisation, but with menstrual 
abnormalities or symptoms suggestive of pelvic 
infection, were excluded). Group C consisted of 25 
patients with suspicions ovarian masses on preoperative 
assessment, but who had noncarcinomatous disorders 
on final diagnosis after surgical exploration.  Patients 
were recruited preoperatively and, after informed 
consent was obtained, blood samples were collected 
for CA125 and SMO47 testing. The biochemist was 
blinded to all patients, and samples were identified by 
study numbers only.
The project was approved by the ethics committees 
of the University of Cape Town, where the monoclonal 
antibody was developed, and by the University 
of Stellenbosch, where the serological assay was 
developed and the patient sampling was performed.
Materials and reagents 
The following materials and reagents were used: 
Maxisorp® ELISA plates from Nunc (Copenhagen, 
Denmark), Hybri-Max Protein-Free RPMI 1640® 
medium from Sigma (Kempton Park, South Africa), 
hydroxyappatite for chromatography from Bio-Rad ( 
Marnes-la-Coquette, France), biotinylated MAL1 (2 mg/
ml) and streptavidin peroxidase (1 mg/ml) from Vector 
Laboratories (Burlingame, CA, USA), and tetramethyl 
benzidine substrate from KPL (Gaithersburg, MD, USA). 
The murine immunoglobulim M (IgM) monoclonal 
antibody SMO47 for antigen capture was developed at 
the University of Cape Town from the spleen of a Balb/c 
mouse immunised with ovarian tumour tissue.
Purification of the SMO47 antibody 
The hybridomas were cultured in protein-free RPMI 
1640 medium, and the spent-culture medium passed 
through a hydroxyappatite column equilibrated with 
10 mM sodium phosphate buffer pH 6.8.10 After washing 
with the buffer, the immunoglobulin was eluted with a 
50-300 mM sodium phosphate gradient in 50 mM steps. 
The eluted antibody was tested electrophoretically for 
purity and was stored at 4°C with 0.05% sodium azide, 
or frozen in aliquots at -80°C.
Performance of the assay 
The principle of the assay is shown diagrammatically in 
Figure 1. The blocking solution was 1% w/v skim milk 
powder in phosphate-buffered saline (PBS), with 0.05% 
azide and the washing solution 0.1% v/v Tween 20 in 
PBS.
Figure 1: Principle of the SM4O7 assay
ELISA plates were coated overnight at 4°C with SMO47 
antibody at 10 µg/ml in PBS (50 µl/well) washed, 
and blocked for a minimum of one hour at room 
temperature. During the blocking step, the diluted 
serum and MAL1 were mixed in Eppendorf tubes, 
and incubated for one hour at room temperature 
(the final dilution of the serum in the mixture was 
1/16, and that of the lectin, 1/320). Duplicate 50 µl 
aliquots were then dispensed into the blocked plates, 
and the plates placed on a slow rotary shaker for one 
hour at room temperature. After washing 50 µl/well, 
streptavidin-peroxidase diluted 1/500 in PBS without 
azide was added, the plate shaken for 30 minutes and, 
after washing again, 100 µl/well tetramethyl benzidine 
substrate. The reaction was stopped after six minutes 
with 100 µl/well of 1M phosphoric acid, and the 
absorbance at 450 nm recorded. The negative control 
was a pool of three normal sera, and the positive control 
was ascites from one of the patients with carcinoma of 
the ovary.
The serum of all the study participants was also tested 
for the CA125 tumour antigen with the Diasorin CA125 
IRMA kit. 
Expression of results
The results for the SMO47 assay were calculated 
by subtracting the mean background absorbance 
(serum substituted by PBS) from the means of 
duplicate test absorbances. These were divided by 
the mean of the ascites absorbance and multiplied 
by 1 000; that is, the ascites, which always gave the 
highest reading, was assigned 1 000 arbitrary units. 
As the test detected sialic acid residues on the 
tumour antigen and not tumour antigen molecules 
themselves, the use of a standard curve was not 
considered appropriate.
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Results 
Group A consisted of 25 confirmed cases of ovarian 
cancer, including serous (n=19), endometroid (n=4), 
mucinous (n=1) and Sertoli-Leydig carcinoma (n=1), as 
shown in Table I. 
Table I: Histological types of ovarian cancer encountered in 
the study
Histology Number
Serous adenocarcinoma 19
Endometroid adenocarcinoma 4
Mucinous adenocarcinoma 1
Sertoli-Leydig cell tumour 1
 Total 25
The patients in group C all had a suspicious mass 
suggestive of ovarian cancer on preoperative 
evaluation, but exploratory surgery confirmed a wide 
range of pathologies (listed in Table II).
Table II: Final diagnoses of patients in Group C
Pathology Number
Postinfective hydrosalpinges 7
Mucinous cystadenoma 2
Uterine fibroids 3
Benign cystic teratoma 2
Corpus haemorrhagicum 2
Endometrial carcinoma 2
Endometrioma  2
Benign Brenner tumour 1
Chronic ectopic pregnancy 1
Gastrointestinal tumour 1
Cystadenofibroma 1
Lymphoma 1
Total 25
Statistical analysis 
The results for the patients with confirmed ovarian 
cancer (group A) were compared to those of the other 
groups by means of the Mann-Whitney test, and 
variation of sensitivity and specificity at different cut-
off values was shown by means of a receiver-operator 
characteristic (ROC) curve from the data of the cancer 
patients and healthy controls. The GraphPad Prism 5 
and Microsoft Office Excel® software was used for the 
graphical representations and statistical calculations.
As the stability and storage properties of the SMO47 
tumour antigen were not known, serum was tested 
blind soon after receipt, and then stored at 4°C with 
0.05% azide and also frozen in aliquots at -20°C 
and -80°C. Tests were repeated several times on the 
unfrozen serum to assess the performance of the test 
and the stability of the antigen. The time between 
the collection of the first and last blood samples 
was two years and three months and the positive 
samples remained positive after storage at 4°C for 
this period, indicating good stability of the antigen. 
As it was a new assay, minor technical modifications 
were made during the course of the testing and, after 
receipt of ascites from patient number 48, this was 
used as reference for the expression of the results 
in preference to a normal serum pool used at the 
start of the testing. The initial tests could therefore 
not be analysed statistically. When blood collection 
was completed, aliquots of the serum stored frozen 
at -20°C were thawed and tested together in one 
ELISA test and, similarly, those frozen at -80°C. Those 
stored at 4°C were tested twice. All these tests were 
completed within nine days. As the antigen was 
stable during the two years of storage at 4°C and 
freezing also did not noticeably affect the results, the 
medians of the results of the four assays were used in 
the graphical representation of the results. 
The ROC curve constructed from the data of the 
cancer patients and the healthy controls is shown in 
Figure 2.  It shows that, when a cut-off value to give 
a specificity of 100% is chosen, the highest sensitivity 
of the test will be 60%. The area under the curve is 
0.8200. The specificity for Group C at this cut-off value 
of 180 is 76%.
Figure 2: ROC curve constructed from the data of the cancer 
patients and healthy controls
The SMO47 test results for the three groups of subjects are 
shown in a scatter plot in Figure 3A, in which the dotted 
line is drawn at a cut-off value of 180 when the specificity 
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is 100% for the healthy controls and the sensitivity 60% 
for the carcinoma patient group. The results for cancer 
patients in Group A with the diagnoses are listed in 
Table III (false negatives in bold type), and the results for 
patients in Group C are listed in Table IV (false positives in 
bold type).  
Figure 3: Test results for SMO47 (3A) and CA125 (3B) of the 
three groups of subjects
As the CA125 test is the most widely used serological 
assay in the diagnosis of carcinoma of the ovary, 
CA125 tests were done on the same serum and the 
results are shown in Figure 3B, where the dotted line 
is at the standard cut-off value or 35 units. The extent 
Table III: Patients with ovarian carcinoma (Group A) (false 
negatives in bold)
Patient 
number
SMO47 
result
Diagnosis
001 463 Serous adenocarcinoma ovary FIGO 
stage 3
002 220 Serous adenocarcinoma ovary FIGO 
stage 3
003 200 Endometrial carcinoma plus left 
carcinosarcoma FIGO stage 3
004 759 Endometrioid adenocarcinoma 
ovary with clear cells FIGO stage 3
005 113 Serous adenocarcinoma ovary 
FIGO stage 3
006 427 Serous adenocarcinoma ovary FIGO 
stage 3
010 88 Mucinous adenocarcinoma ovary 
FIGO stage 3
014 77 Serous adenocarcinoma ovary 
FIGO stage 3
018 391 Sertoli Leydig cell tumour FIGO 
stage 1
020 243 Endometrioid adenocarcinoma 
ovary FIGO stage 3
021 762 Serous adenocarcinoma ovary FIGO 
stage 1
022 143 Endometrioid adenocarcinoma 
ovary FIGO stage 2
026 278 Serous adenocarcinoma ovary FIGO 
stage 3
027 333 Serous adenocarcinoma ovary FIGO 
stage 3
029 415 Serous adenocarcinoma  ovary FIGO 
stage 3
040 70 Serous adenocarcinoma ovary 
FIGO stage 3
048 910 Serous adenocarcinoma ovary FIGO 
stage 4
052 74 Serous adenocarcinoma ovary 
FIGO stage 3
055 516 Serous adenocarcinoma ovary FIGO 
stage 3
057 139 Serous adenocarcinoma ovary 
FIGO stage 2
064 73 Serous adenocarcinoma ovary 
FIGO stage 3
066 122 Endometrioid adenocarcinoma 
ovary FIGO stage 3
068 655 Serous adenocarcinoma ovary FIGO 
stage 4
070 66 Serous adenocarcinoma ovary 
FIGO stage 3
073 383 Serous adenocarcinoma ovary FIGO 
stage 3
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of agreement between SMO47 and CA125 results is 
illustrated in Figure 4 for cancer patients (Figure 4A), 
healthy controls (Figure 4B) and control patients 
(Figure 4C). The dotted lines are at the cut-off value 
of 35 for CA125 and 180 for SMO47. The data points 
in the four quadrants made by the dotted lines thus 
show: the number of sera positive for both CA125 
and SMO47 (upper right quadrant); those positive for 
CA125 and negative for SMO47 (lower right); those 
negative for CA125 and positive for SMO47 (upper 
left); and those negative for both tests (lower left). 
The diagnoses of patients in Group A whose sera 
were positive for CA125 and negative for SMO47 are 
listed in Table V.
Table IV: Patients with other pathologies (Group C) (false 
positives in bold)
Patient 
number
SMO47 
result
Diagnosis
007 150 Papillary serous cystadenofibroma 
(benign)
008 69 Pelvic inflammatory disease
009 298 Pelvic inflammatory disease
019 50 Gastrointestinal tumour
023 554 Mucinous cystadenoma of ovary 
(benign)
024 0 Grade II follicular lymphoma
025 276 Benign cystic teratoma
028 38 Corpus haemorrhagicum and en-
dometriosis
031 52 Uterine leiomyoma
034 110 Pelvic inflammatory disease
035 72 Endometrial adenocarcinoma (of the 
uterus) 
036 51 Chronic inflammation
037 149 Borderline mucinous ovarian tumour
038 120 Papillary serous adenocarcinoma (of 
the endometrium)
041 25 Endometrioma (benign)
042 47 Cystic atypical Brenner tumour of 
ovary
043 34 Chronic ectopic pregnancy
076 152 Salpingitis
077 94 Uterine leiomyoma
078 77 Benign cystic teratoma
079 193 Haemorrhagic corpus luteum cyst
080 99 Uterine leiomyoma
083 311 Endometriosis
084 72 Endometrial polyp with chronic 
salpingitis
085 201 Acute-on-chronic salpingitis
Figure 4: Extent of agreement between SMO47 and CA125 
for patients with cancer (4A), healthy controls (4B) and control 
patients (4C)
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Discussion
At present, there is no effective, single biomarker for 
screening for ovarian cancer, and the results of the 
exploratory study presented here are therefore of 
interest. The SMO47assay did not detect some of the 
ovarian carcinomas and was positive in some patients 
with other pathological conditions, but this is also seen 
with tests for other markers. The assay had a good 
specificity in normal subjects. 
The effect of sampling in small numbers of patients is 
illustrated by the finding of 100% sensitivity for CA125 
in our group of patients with carcinoma. It is well 
established in general clinical practice that sensitivity 
is only approximately 80% overall.4,12
The function of the normal SMO47 antigen is not 
known, and the purpose of sialylation by the tumour 
cells could be to avoid recognition by immune cells, 
because sialic acids can act as biological masks.24 On 
the other hand, sialylated and sometimes sulphated 
recognition structures could trigger responses by cells 
of the immune system and other leukocytes, platelets 
and endothelium that express proteins known to bind 
sialic acid. These proteins are the selectins, which 
have been associated with the spread of epithelial 
tumour cells via the bloodstream.25 Siglecs (sialic acid-
recognising immunoglobulin superfamily lectins) are 
a subfamily of sialic acid-binding proteins that share 
homology with variable and constant domains of 
immunoglobulins (e.g. CD22, CD33 and sialo-adhesin) 
which are expressed differentially in cells of the 
haematopoietic system.26 Siglecs have two conserved 
motifs resembling immune-receptor tyrosine-based 
inhibition motifs (ITIMS) in their cytoplasmic tails, 
and may thus be involved in down-regulation of the 
activated immune system.
The reasons why the sialylated antigen is not found 
in the bloodstream of 40% of the patients with 
cancer in this study would be of interest in relation 
to the prognosis and the metastatic potential of 
the tumour. Of relevance in this respect could be an 
interesting finding that humans, who can produce 
the sialic acid N-acetylneuraminic acid (Neu5Ac) 
but not N-glycolylneuraminic acid (Neu5Gc) (as a 
result of a deletion mutation in the CMAH gene), can 
metabolically incorporate the latter from red meat 
and dairy products in the diet.27 This can then trigger 
immune responses to the non-human Neu5Gc, which 
is the mechanism of the “serum sickness” reaction 
described by Hanganutziu and Deicher early in the 20th 
century. These Hanganutziu-Deicher (HD) antibodies 
were found to react with Neu5Gc bound to horse 
serum glycoconjugates, and were then discovered in 
the serum and tissues of patients with cancer28 and in 
activated and malignant immune cells.29 Antibodies 
of varying isotypes were found in many or all normal 
human subjects,27,29 and their binding to cells can 
result in complement-mediated cytotoxicity. If some 
ovarian cancer patients have HD antibodies, they could 
be responsible for neutralising the secreted SMO47 
Table V: Patients with ovarian carcinoma (Group A), positive 
for CA125 and negative for SMO47
Patient 
number
CA125 SMO47 Diagnosis
005 74.0 113 Serous adenocarcinoma 
ovary FIGO stage 3
010 65.9 88 Mucinous 
adenocarcinoma ovary 
FIGO stage 3
014 1 501.0 77 Serous adenocarcinoma 
ovary FIGO stage 3
022 81.9 143 Endometrioid 
adenocarcinoma ovary 
FIGO stage 2
040 471.7 70 Serous adenocarcinoma 
ovary FIGO stage 3
052 986.0 74 Serous adenocarcinoma 
ovary FIGO stage 3
057 228.0 139 Serous adenocarcinoma 
ovary FIGO stage 2
064 588.0 73 Serous adenocarcinoma 
ovary FIGO stage 3
066 7 061.0 122 Endometrioid 
adenocarcinoma ovary 
FIGO stage 3
070 505.0 66 Serous adenocarcinoma 
ovary FIGO stage 3
Figure 5: The coefficients of variation of the four repeated 
tests for each serum sample versus means of the test results
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antigen, if it contains Neu5Gc. (MAL1 binds to both 
Neu5Ac and Neu5Gc.)30 
The limitations of this study are the following:
•	 The number of subjects tested in each group of 
patients is too small to make significant statistical 
comparisons, and an assessment of its clinical value 
cannot be made until after a further larger-scale 
study.
•	 The cut-off value of 180, which was chosen to 
ensure 100% specificity in the healthy control 
subject group, may not be optimal.
•	 The methodology of the test is completely new and 
may not be optimal yet. 
However, we suggest some positive aspects of the 
study:
•	 The test achieved a reasonable negative predictive 
value in the group of patients with other pathologies.
•	 The SMO47 antibody reacts well with 
routinely processed tissue sections,21 and 
immunecytochemistry can complement the 
test findings. 
•	 The tumour antigen is stable. The coefficients of 
variation of the assay repeats at four times are 
plotted versus the means of the tests in Figure 5.
Conclusion
In conclusion, the chemical nature of the normal and 
tumour-associated SMO47 antigen is largely unknown. 
The serological assay for SMO47 must be studied in 
larger numbers of cancer patients and normal subjects 
in order assess its performance and clinical relevance. 
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